Nayagarh,(Baghuabarta): U.S. regulators are delaying their decision on Moderna’s COVID-19 vaccine for 12- to 17-year-olds while they study the rare risk of heart inflammation, the company said Sunday. The U.S. Food and Drug Administration told the company Friday evening that its review could last until January, Moderna said. The company also said it will delay filing a request for emergency-use authorization of a lower dose of the vaccine for 6- to 11-year-olds.
FDA Delaying Decision On Its Shot For Adolescents: Moderna
